

CERTIFICATE OF ELECTRONIC FILING

This correspondence is being transmitted to the Commissioner for Patents, Alexandria, VA, via the Office electronic filing system in accordance with 37 C.F.R. § 1.6(a)(4), on the date below:

May 1, 2007

Date



Sharon V. Hart

**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe and Sophia Ran

Serial No.: 09/998,833

Filing Date: November 30, 2001

For: Combined Cancer Treatment Methods  
Using Antibodies to Aminophospholipids  
(As Amended)

Group Art Unit: 1642

Examiner: Fetterolf, B.

Atty. Dkt. No.: 4001.002299

**APPLICANTS' INTERVIEW SUMMARY**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants' representatives have just received the Examiner's Interview Summary dated March 27, 2007, for a telephone interview held March 15, 2007.

The present document is Applicants' Interview Summary. Applicants concur with the Examiner's Interview Summary dated March 27, 2007.

The Examiner's Interview Summary sets a one month period for Applicants to submit Applicants' Interview Summary. However, Applicants could not submit their summary prior to receipt of the Examiner's Interview Summary, which has just arrived. The present document is being submitted promptly after receipt of the Examiner's Interview Summary, and is therefore as timely as possible.

No fees or petitions should be due in regard to the present document. However, should any petition(s) be deemed necessary for any reason relating to the present document, including a petition to withdraw a holding of abandonment, or petition(s) to revive an unavoidably or unintentionally abandoned application, this paper should be considered as the required petition. Any petition or other fees deemed necessary under 37 C.F.R. §§ 1.16 to 1.21 should be deducted from Peregrine Pharmaceuticals, Inc. Deposit Account No. 50-3493/4001.002299.

Should Examiner Fetterolf have any questions or comments, a telephone call to the undersigned Applicants' representative is earnestly solicited.

Respectfully submitted,

PEREGRINE PHARMACEUTICALS, INC.  
Customer No. 000052101



Shelley P.M. Fussey, Ph.D.  
Reg. No. 39,458  
Agent for Applicants

5353 W. Alabama, Suite 306  
Houston, Texas, 77056  
(713) 439 0108

Date: May 1, 2007